Neuromyelitis optica (NMO) is a rare autoimmune disease that affects the optic nerves and spinal cord. It is characterized by inflammation of the optic nerve and spinal cord, leading to severe pain, blindness, paralysis and other neurological symptoms. The disease can be difficult to diagnose because it shares many of the same symptoms as multiple sclerosis (MS). NMO is caused by an antibody called anti-aquaporin 4 antibody (AQP4-Ab), which attacks cells in the central nervous system that produce water channels called aquaporins. AQP4-Ab can also attack cells in other parts of the body such as kidneys, lungs or skin.
Glucocorticoids are used for acute attack treatment while immunotherapies are used for remission prophylactic treatment. Glucocorticoids are prescribed for acute attack treatment while immunotherapies are prescribed for remission prophylactic treatment. Glucocorticoids have been found to be effective in reducing relapse rates among patients with NMO who have had an acute attack but not yet reached remission; however, they do not seem to affect long term disability rates or progression of disability among patients with NMO who have already reached remission status.
Some Of The Growth Factors Of This Market:
- The market for neuromyelitis optica drugs is expected to reach $1,890 million by 2025.
- Neuromyelitis Optica (NMO) is an autoimmune disease that affects the optic nerves and spinal cord, causing inflammation and damage.
- NMO can lead to blindness, paralysis, and other neurological problems.
- NMO can be treated with immunosuppressive medications such as corticosteroids or intravenous immunoglobulin.
Industry Growth Insights published a new data on “Neuromyelitis Optica Drug Market”. The research report is titled “Neuromyelitis Optica Drug Market research by Types (Glucocorticoids, Immunotherapies, Other, Neuromyelitis Optica Dru), By Applications (Acute attack, Remission Prophylactic Treatment), By Players/Companies Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP, Neuromyelitis Optica Dru”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Neuromyelitis Optica Drug Market Research Report
By Type
Glucocorticoids, Immunotherapies, Other, Neuromyelitis Optica Dru
By Application
Acute attack, Remission Prophylactic Treatment
By Companies
Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP, Neuromyelitis Optica Dru
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Neuromyelitis Optica Drug Market Report Segments:
The global Neuromyelitis Optica Drug market is segmented on the basis of:
Types
Glucocorticoids, Immunotherapies, Other, Neuromyelitis Optica Dru
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute attack, Remission Prophylactic Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Fresenius
- Teva
- Sandoz
- Intas
- Gyjtrs
- NANG KUANG
- Tianjin Kingyork
- Baxter
- CSL
- Grifols
- Octapharma
- CBOP
- Neuromyelitis Optica Dru
Highlights of The Neuromyelitis Optica Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Glucocorticoids
- Immunotherapies
- Other
- Neuromyelitis Optica Dru
- By Application:
- Acute attack
- Remission Prophylactic Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neuromyelitis Optica Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neuromyelitis optica (NMO) is a rare, chronic inflammatory disease of the optic nerve. The optic nerve is a bundle of fibers that carries visual information from the eyes to the brain. NMO can damage this delicate fiberoptic cable, leading to vision loss and other neurological problems. There is no cure for NMO, but there are treatments available that can help improve symptoms. Some common medications used to treat NMO include corticosteroids and antiviral drugs.
Some of the major players in the neuromyelitis optica drug market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP, Neuromyelitis Optica Dru.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Neuromyelitis Optica Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Neuromyelitis Optica Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Neuromyelitis Optica Drug Market - Supply Chain
4.5. Global Neuromyelitis Optica Drug Market Forecast
4.5.1. Neuromyelitis Optica Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Neuromyelitis Optica Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Neuromyelitis Optica Drug Market Absolute $ Opportunity
5. Global Neuromyelitis Optica Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Neuromyelitis Optica Drug Market Size and Volume Forecast by Type
5.3.1. Glucocorticoids
5.3.2. Immunotherapies
5.3.3. Other
5.3.4. Neuromyelitis Optica Dru
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Neuromyelitis Optica Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Neuromyelitis Optica Drug Market Size and Volume Forecast by Application
6.3.1. Acute attack
6.3.2. Remission Prophylactic Treatment
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Neuromyelitis Optica Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Neuromyelitis Optica Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Neuromyelitis Optica Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Neuromyelitis Optica Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Neuromyelitis Optica Drug Demand Share Forecast, 2019-2026
9. North America Neuromyelitis Optica Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Neuromyelitis Optica Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Neuromyelitis Optica Drug Market Size and Volume Forecast by Application
9.4.1. Acute attack
9.4.2. Remission Prophylactic Treatment
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Neuromyelitis Optica Drug Market Size and Volume Forecast by Type
9.7.1. Glucocorticoids
9.7.2. Immunotherapies
9.7.3. Other
9.7.4. Neuromyelitis Optica Dru
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Neuromyelitis Optica Drug Demand Share Forecast, 2019-2026
10. Latin America Neuromyelitis Optica Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Neuromyelitis Optica Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Neuromyelitis Optica Drug Market Size and Volume Forecast by Application
10.4.1. Acute attack
10.4.2. Remission Prophylactic Treatment
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Neuromyelitis Optica Drug Market Size and Volume Forecast by Type
10.7.1. Glucocorticoids
10.7.2. Immunotherapies
10.7.3. Other
10.7.4. Neuromyelitis Optica Dru
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Neuromyelitis Optica Drug Demand Share Forecast, 2019-2026
11. Europe Neuromyelitis Optica Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Neuromyelitis Optica Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Neuromyelitis Optica Drug Market Size and Volume Forecast by Application
11.4.1. Acute attack
11.4.2. Remission Prophylactic Treatment
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Neuromyelitis Optica Drug Market Size and Volume Forecast by Type
11.7.1. Glucocorticoids
11.7.2. Immunotherapies
11.7.3. Other
11.7.4. Neuromyelitis Optica Dru
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Neuromyelitis Optica Drug Demand Share, 2019-2026
12. Asia Pacific Neuromyelitis Optica Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Neuromyelitis Optica Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Neuromyelitis Optica Drug Market Size and Volume Forecast by Application
12.4.1. Acute attack
12.4.2. Remission Prophylactic Treatment
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Neuromyelitis Optica Drug Market Size and Volume Forecast by Type
12.7.1. Glucocorticoids
12.7.2. Immunotherapies
12.7.3. Other
12.7.4. Neuromyelitis Optica Dru
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Neuromyelitis Optica Drug Demand Share, 2019-2026
13. Middle East & Africa Neuromyelitis Optica Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Neuromyelitis Optica Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Neuromyelitis Optica Drug Market Size and Volume Forecast by Application
13.4.1. Acute attack
13.4.2. Remission Prophylactic Treatment
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Neuromyelitis Optica Drug Market Size and Volume Forecast by Type
13.7.1. Glucocorticoids
13.7.2. Immunotherapies
13.7.3. Other
13.7.4. Neuromyelitis Optica Dru
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Neuromyelitis Optica Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Neuromyelitis Optica Drug Market: Market Share Analysis
14.2. Neuromyelitis Optica Drug Distributors and Customers
14.3. Neuromyelitis Optica Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Fresenius
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Teva
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sandoz
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Intas
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Gyjtrs
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. NANG KUANG
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Tianjin Kingyork
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Baxter
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CSL
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Grifols
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Octapharma
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. CBOP
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Neuromyelitis Optica Dru
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
